Boston Scientific is buying Veniti, a firm that has developed a stent system for treating venous obstructive disease, in a deal worth up to $160 million.
FDA extended the indication for Cianna Medical's Scout reflector, allowing the device to be used to mark soft tissue sites including lymph nodes.
Some of medtech’s largest companies are working for approval in the TMVR space, which could one day rival or surpass TAVR.
The two technology groups will collaborate to expand SCHOTT’s hermetic packaging portfolio with an innovative new glass micro bonding technology that will create new possibilities for electronic implantable devices.
Abbott acquired Tendyne back in 2015, a year where there was significant M&A activity in the transcatheter mitral valve replacement space.
With more investments and potential device clearances on the way, the Bioelectronics market is beginning to take off.
The Natick, MA-based company has just completed enrollment in the ENLIGHTEN clinical trial and could have topline results from the study available in 2019.
Bayer plans to discontinue sales of the Essure birth control implant in the United States, citing a decline in U.S. sales of the device.
Cleveland Clinic physicians have completed a study that shows leadless pacemakers might be a safer option than traditional transvenous pacemakers.
Glaukos has the potential to extend its lead into the MIGS market with the approval of the iStent inject Trabecular Micro-Bypass System.
Senseonics has received a PMA for the sensor out to 90 days, but plans call for a 180-day version of the device and eventually a version that lasts for a year.
Dexcom could face even more intense pressure in the CGM market now that Senseonics said its Eversense system has approval. The device could provide long-term continuous monitoring for up to three months.
A Massachusetts jury backed Boston Scientific in a product liability case involving two of the company's transvaginal mesh devices.